Thermo Fisher Scientific CD30 Monoclonal Antibody (Ber-H2), FITC, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (0.125 µg)/test

-

Product Specifications

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), FITC, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

Ber-H2

Conjugate

FITC FITC FITC

View additional formats

• APC
• PE
• PE-Cyanine7
• Super Bright 702
• Request custom conjugation

Excitation/Emission Max

498/517 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Wet ice

RRID

AB_2572450

Product Specific Information

Description: The Ber-H2 monoclonal antibody reacts with human CD30, a 120 kDa transmembrane glycoprotein of the TNFR superfamily. CD30 is expressed on normal activated cells, T and B lymphocytes but not resting lymphocytes. Expression is also found on some lymphomas and embryonal carcinomas as well as HIV, HTLV and EBV infected lymphocytes. Interaction with its ligand, CD30L, leads to signaling and activation of NK kappa B and subsequently regulates apoptosis.

Applications Reported: This Ber-H2 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This Ber-H2 antibody has been pre-titrated and tested by flow cytometric analysis of stimulated normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin`s lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL). CD30 is also expressed by embryonal carcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.